long-chain acyl-coa synthetase 4

Triacsin C (WS 1228A) from Streptomyces aureofaciens is a differential inhibitor of arachidonic acid coenzyme A synthetase and non-specific long-chain acyl-coenzyme A synthetase, with anti-atherosclerotic activity, inhibition of ACSL activity, and inhibition of the accumulation of TAGs into lipid droplets (LDs).Triacsin C has been used to study rotavirus infection and Alzheimer;s disease. Triacsin C is used to study rotavirus infection and Alzheimer;s disease.

PRGL493 is an inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4).1It inhibits formation of arachidonoyl-CoA (AA-CoA) from arachidonic acid in, as well as the proliferation and migration of, PC3 and MDA-MB-231 cancer cells when used at a concentration of 50 μM. PRGL493 (5 μM) reduces production of progesterone induced by 8-Br-cyclic AMP (8-Br-cAMP) in MA-10 Leydig tumor cells. It inhibits tumor growth in a PC3 mouse xenograft model when administered at a dose of 0.25 mg/kg.

LIBX-A401 is an inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4) with an IC50 value of 0.38 μM. It selectively inhibits ACSL4 over ACSL3 (IC50 exceeding 50 μM) and PPARγ (IC50 exceeding 10 μM).

LIBX-A403 (Compound 21) is a highly selective inhibitor of acyl-CoA synthetase long-chain family member 4 (ACSL4) with an IC50 of 0.049 μM. It prevents ACSL4-mediated pro-ferroptotic phospholipid remodeling. LIBX-A403 shows potential for research in cancer, such as triple-negative breast cancer, and neurodegenerative disorders like Parkinson's disease.